The authors found a 2-3 times higher risk of unemployment in patients who had a stroke between the ages of 18 and 50 years, compared to the general population. The risk for unemployment among stroke patients was highest in patients who had a stroke between 35 and 44 years of age. In poststroke care for young patients, attention should be given to the social consequences that they may encounter.
See p. 1132
From editorialists Singhal & Lo: "Perhaps we need to start incorporating 'return to work' as a global outcome measure that assesses the efficacy of multidisciplinary treatment strategies for any working individual who develops a stroke." Midodrine for orthostatic hypotension and recurrent reflex syncope: A systematic review Midodrine's safety and efficacy for the management of patients with orthostatic hypotension and recurrent reflex syncope remains unknown. The authors found a low/moderate quality of evidence suggesting that midodrine may improve patientimportant outcomes. Midodrine should be considered as a therapeutic alternative in the management of these patients.
See p. 1170
Asymmetry of cortical decline in subtypes of primary progressive aphasia Changes in cortical thickness and volume loss as well as neuropsychological performance were assessed in 26 patients who fulfilled criteria for logopenic, agrammatic, and semantic primary progressive aphasia (PPA) subtypes. Clinical deficits and cortical atrophy patterns showed distinct patterns of change among the subtypes over 2 years. Using a focal cortical language network region of interest as an outcome measure of disease progression is more sensitive and may help for designing future clinical trials in PPA. The authors measured NT-proBNP levels and blood pressure at age 85 years, at baseline, and global cognitive function annually in 560 patients followed for 5 years. The combination of high NT-proBNP levels and low systolic blood pressure was associated with the worst global cognitive function and the steepest cognitive decline.
See p. 1192
Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes TERT promoter mutation (TERTp-mut), EGFR amplification, and IDH1 mutation analysis define 4 prognostic subgroups of glioblastomas. Survival ranged from 13-14 months when TERTp-mut or EGFR amplification was present to 2-3 years (depending on IDH1 status) when both alterations were absent.
See p. 1200
Podcasts can be accessed at Neurology.org NB: "Concussed," see p. 1126. To check out this editorial, point your browser to Neurology.org.
